NASDAQ:EVFMEvofem Biosciences Stock Price, Forecast & News

Evofem Biosciences' stock was trading at $5.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EVFM shares have decreased by 35.9% and is now trading at $3.31. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evofem Biosciences.

Evofem Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Evofem Biosciences.

Evofem Biosciences Inc (NASDAQ:EVFM) issued its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.08. View Evofem Biosciences' earnings history.

4 Wall Street analysts have issued 1-year target prices for Evofem Biosciences' stock. Their forecasts range from $6.00 to $25.00. On average, they anticipate Evofem Biosciences' share price to reach $12.75 in the next twelve months. This suggests a possible upside of 285.2% from the stock's current price. View analysts' price targets for Evofem Biosciences.

Media headlines about EVFM stock have trended very positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Evofem Biosciences earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an effect on the company's share price in the immediate future. View the latest news aboutEvofem Biosciences.

Evofem Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,140,000 shares, an increase of 41.7% from the April 30th total of 1,510,000 shares. Based on an average daily volume of 173,900 shares, the short-interest ratio is presently 12.3 days. Approximately 6.3% of the company's shares are sold short. View Evofem Biosciences' Current Options Chain.

Some companies that are related to Evofem Biosciences include ZIOPHARM Oncology (ZIOP), Akero Therapeutics (AKRO), Sinovac Biotech (SVA), Assembly Biosciences (ASMB), Vanda Pharmaceuticals (VNDA), Stemline Therapeutics (STML), DiaMedica Therapeutics (DMCAF), Ardelyx (ARDX), Syndax Pharmaceuticals (SNDX), Dynavax Technologies (DVAX), Trillium Therapeutics (TRIL), Radius Health (RDUS), Frequency Therapeutics (FREQ), Aprea Therapeutics (APRE) and Athersys (ATHX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evofem Biosciences investors own include Anavex Life Sciences (AVXL), Momo (MOMO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Nabriva Therapeutics (NBRV), Catalyst Pharmaceuticals (CPRX), Interpace Diagnostics Group (IDXG) and Marinus Pharmaceuticals (MRNS).

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

Evofem Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.01%), Schroder Investment Management Group (6.42%), State Street Corp (0.55%), Geode Capital Management LLC (0.53%), Squarepoint Ops LLC (0.07%) and Oppenheimer & Co. Inc. (0.06%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Justin J File, Kelly Culwell, Kim P Kamdar, Ltd Invesco, Pdl Biopharma, Inc, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View institutional ownership trends for Evofem Biosciences.

EVFM stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, UBS Group AG, State Street Corp, and Deutsche Bank AG. Company insiders that have sold Evofem Biosciences company stock in the last year include Justin J File, Kelly Culwell, Russell Barrans, and Saundra L Pelletier. View insider buying and selling activity for Evofem Biosciences.

EVFM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Squarepoint Ops LLC, Oppenheimer & Co. Inc., and Geode Capital Management LLC. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Pdl Biopharma, Inc, Russell Barrans, Saundra L Pelletier, and Thomas G Lynch. View insider buying and selling activity for Evofem Biosciences.

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EVFM stock can currently be purchased for approximately $3.31.

Evofem Biosciences has a market capitalization of $164.58 million. The biotechnology company earns $-80,030,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Evofem Biosciences employs 30 workers across the globe.

The official website for Evofem Biosciences is www.evofem.com.

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]